Therapeutic Response

ER negative, HER2-negative, PD-L1 (CPS) >= 10, and PR negative status confers therapeutic sensitivity to Pembrolizumab in combination with Sacituzumab govitecan in patients with Invasive Breast Carcinoma.

Statements

Source and description

Trodelvy (sacituzumab govitecan) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to sacituzumab govitecan, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 [Combined Positive Score (CPS >= 10)] as determined by an FDA-authorized test.